SCHEMBL3767445

SCHEMBL3767445

CCN(C(=O)c1cccc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c1)C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TSHR P16473 1/20 0.46
MAPT P10636 3/20 0.44
L3MBTL3 Q96JM7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ACACB O00763 1/20 0.41
ACACA Q13085 1/20 0.41
KDM4E B2RXH2 3/20 0.41
HIF1A Q16665 1/20 0.41
HRH3 Q9Y5N1 3/20 0.41
POLB P06746 1/20 0.40
BRD4 O60885 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765974 0.89 ALDH1A1 (0.48) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL3768093 0.89 HRH3 (0.46) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL3769406 0.86 MEN1 (0.46) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL13006807 0.84 MEN1 (0.54) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL3772414 0.84 MEN1 (0.47) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL3761030 0.82 L3MBTL1 (0.65) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL3774006 0.82 L3MBTL1 (0.65) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL3777294 0.81 HRH3 (0.48) HRH3
SCHEMBL3762737 0.81 L3MBTL1 (0.67) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL3763154 0.81 MEN1 (0.55) ALDH1A1LMNAMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885LMNA 2902/4885MEN1 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.